QLGN vs. ALLR, PRFX, ATNF, PXMD, INM, CMND, BPTH, GLMD, NBSE, and DRMA
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Allarity Therapeutics (ALLR), PainReform (PRFX), 180 Life Sciences (ATNF), PaxMedica (PXMD), InMed Pharmaceuticals (INM), Clearmind Medicine (CMND), Bio-Path (BPTH), Galmed Pharmaceuticals (GLMD), NeuBase Therapeutics (NBSE), and Dermata Therapeutics (DRMA). These companies are all part of the "pharmaceutical preparations" industry.
Qualigen Therapeutics (NASDAQ:QLGN) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
Allarity Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.
3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 5.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Allarity Therapeutics had 7 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 8 mentions for Allarity Therapeutics and 1 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 1.89 beat Allarity Therapeutics' score of 0.34 indicating that Qualigen Therapeutics is being referred to more favorably in the media.
Allarity Therapeutics has lower revenue, but higher earnings than Qualigen Therapeutics.
Qualigen Therapeutics has a beta of -0.73, suggesting that its stock price is 173% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500.
Qualigen Therapeutics received 6 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote.
Summary
Allarity Therapeutics beats Qualigen Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
